(29c) Keynote Speaker - Omid Veiseh, Assistant Professor of Bioengineering, Rice University

Omid Veiseh’s laboratory utilizes advanced nano, micro, and macro fabrication techniques in combination with molecular engineering and cellular and molecular biology, to develop platforms of implantable devices tailored for in vivo chemical sensing and delivery of therapeutics. The Veiseh laboratory is particularly interested in developing technologies for the improved management of cancer, Type-1 diabetes, rheumatoid arthritis, and other autoimmune diseases.

Dr. Omid Veiseh, Ph.D., is an Assistant Professor and CPRIT Scholar in Cancer Research in the Department of Bioengineering at Rice University. He is a bioengineer and entrepreneur leading a cutting-edge research program aimed at developing and commercializing immunotherapy innovations towards improving human health. His discoveries have translated into therapeutic products that are in various stages of clinical testing for the treatment of blood disorders, metabolic disorders, Type-1 Diabetes, and Cancer.

Dr. Veiseh received a dual Ph.D. in Materials Science & Engineering and Nanotechnology from the University of Washington. He completed his postdoctoral research with Prof. Robert Langer and Prof. Daniel Anderson at MIT and Harvard Medical School. Over the course of his career he has authored, or co-authored more than 60 peer-reviewed publications including those in Nature, Nature Biotechnology, Nature Materials, Nature Medicine, Nature Biomedical Engineering and is an inventor on more than 30 pending or awarded patents. He has co-founded four biotechnology companies based on his research efforts to date, namely, Sigilon Therapeutics (Nasdaq : SGTX), Avenge Bio, Pana Bio, and Curada Bio.